Epstein-Barr virus (EBV) is one of the most widespread infections in humans. More than 95% of people worldwide carry the virus, with most picking it up during childhood or early adulthood. In the United States specifically, about 9 out of 10 adults have antibodies showing a current or past infection. If you’ve been wondering whether EBV is rare, the answer is the opposite: it’s nearly universal.
Why Almost Everyone Has It
EBV spreads primarily through saliva, which is why mononucleosis (the illness it sometimes causes) earned the nickname “the kissing disease.” But sharing drinks, utensils, or food with someone carrying the virus is enough. Parents routinely pass it to young children this way without anyone realizing it.
What makes EBV so pervasive is that carriers don’t need to feel sick to spread it. On any given day, roughly 20 to 25% of people who carry the virus are actively shedding it in their saliva. That means a quarter of the adults around you could be releasing infectious virus particles right now with no symptoms whatsoever. Once you’re infected, the virus stays in your body for life, periodically reactivating and shedding without causing noticeable illness.
Most Infections Go Unnoticed
The timing of your first EBV infection matters more than the infection itself. Children who catch it, typically before age five, almost never develop symptoms. The virus quietly sets up a lifelong residence in certain immune cells, and the child’s body controls it without any drama.
Teenagers and young adults are the ones who tend to get sick. When someone encounters EBV for the first time during adolescence, there’s a significant chance of developing infectious mononucleosis: weeks of extreme fatigue, sore throat, swollen lymph nodes, and sometimes an enlarged spleen. Recovery takes two to four weeks for most people, though the fatigue can linger for months. In lower-income countries, where children are exposed earlier through crowded living conditions and shared food, symptomatic mono is far less common. In wealthier countries where hygiene delays first exposure until the teen years, mono is a familiar diagnosis on college campuses.
EBV and Cancer Risk
For the vast majority of people, carrying EBV causes no long-term problems. But the virus is directly linked to several cancers, including certain lymphomas (such as Burkitt lymphoma and Hodgkin lymphoma), nasopharyngeal carcinoma, and roughly 10% of stomach cancers. Globally, these EBV-associated cancers account for an estimated 240,000 to 358,000 new cases and 138,000 to 209,000 deaths per year.
Those numbers sound alarming until you put them in context. With more than 95% of the world’s population carrying the virus, the fraction who develop an EBV-related cancer is extremely small. The cancers tend to involve additional risk factors, including genetics, immune suppression, and environmental exposures, that combine with the virus to trigger disease. Carrying EBV alone is not a reason to worry about cancer.
The Link to Multiple Sclerosis
One of the most significant discoveries in recent years is the connection between EBV and multiple sclerosis. A landmark study tracking millions of military personnel found that EBV infection dramatically increases the risk of developing MS. People who had symptomatic mononucleosis specifically face more than three times the risk of MS compared to the general population.
This doesn’t mean mono causes MS in any simple sense. MS remains a rare disease, so tripling a small risk still leaves the absolute chance low. But the association is strong enough that researchers now consider EBV a necessary trigger for MS in most cases, with nearly all MS patients showing evidence of prior EBV infection. This has made developing an EBV vaccine a priority for neurological research as well as infectious disease prevention.
No Vaccine Yet, but Candidates Are in Development
Despite EBV being one of the most common human viruses and a known contributor to cancer and autoimmune disease, no approved vaccine exists. That’s partly because the virus is so ubiquitous that designing trials is challenging, and partly because EBV-related diseases take years or decades to appear after infection, making it hard to prove a vaccine prevents them.
Several vaccine candidates are now in early clinical trials. At least one mRNA-based vaccine is entering Phase 1 testing in healthy young adults in Australia, with results expected by 2027. These early trials focus on safety and whether the vaccine produces an immune response, not yet on whether it prevents infection in the real world. Even in the best-case scenario, an EBV vaccine is likely years away from widespread availability.
What Carrying EBV Means for You
If you’re an adult, you almost certainly already have EBV. That’s not a diagnosis to lose sleep over. The virus sits quietly in your immune cells, occasionally reactivating at low levels, and your immune system keeps it in check. You won’t test positive on a standard screening unless you specifically ask for EBV antibody testing, and most doctors don’t recommend routine testing because the results rarely change anything about your care.
The situations where EBV becomes clinically relevant are narrow: if you develop unexplained fatigue and swollen glands (suggesting acute mono), if you’re undergoing immune-suppressing treatment like an organ transplant, or if you’re being evaluated for one of the cancers or autoimmune conditions linked to the virus. For everyone else, EBV is simply part of being human, a near-universal companion that the immune system has learned to manage.